Cellectar Biosciences
CLRB
30 hedge funds and large institutions have $1.52M invested in Cellectar Biosciences in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 10 closing their positions.
367% more call options, than puts
Call options by funds: $14K | Put options by funds: $3K
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
0.89% less ownership
Funds ownership: 1.3% → 0.41% (-0.89%)
14% less funds holding
Funds holding: 35 → 30 (-5)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
95% less capital invested
Capital invested by funds: $30M → $1.52M (-$28.4M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$802K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$576K |
| 3 |
JP Morgan Chase
New York
|
+$245K |
| 4 |
Two Sigma Investments
New York
|
+$110K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$64.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$7.86M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$6.84M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$5.8M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$673K |
| 5 |
Barclays
London,
United Kingdom
|
-$258K |
CLRB Hedge Fund Activity: Q4 2024 in Review
30 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2024, worth a combined $1.52M — down 95% from $30M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CLRB and 6 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 11 added.
The largest buyer was Squarepoint, opening a new position worth an estimated $802K. The largest seller was Rosalind Advisors, exiting entirely with an estimated $7.86M sold.
- 30 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2024, down from 35 in Q3 2024.
- Funds reported $1.52M of Cellectar Biosciences stock for Q4 2024, down 95% quarter-over-quarter.
- 6 funds opened new Cellectar Biosciences positions in Q4 2024 and 10 closed out, a net change of -4 holders.
- The largest Cellectar Biosciences buyer in Q4 2024 was Squarepoint, an estimated $802K added.
- The largest Cellectar Biosciences seller in Q4 2024 was Rosalind Advisors, an estimated $7.86M sold.
Based on aggregated 13F filings for Q4 2024.